Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation (Tables)

Share-based compensation (Tables)

9 Months Ended

Sep. 30, 2020

Summary of share-based compensation expense included in the unaudited consolidated statements of operations

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended			Nine months ended
		September 30,			September 30,
	2020		2019		2020		2019
Research and development	$	1,219	$	144	$	3,126	$	2,951
General and administrative		2,061		1,676		4,226		5,544
	$	3,280	$	1,820	$	7,352	$	8,495

Summary of all stock option activity

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended			Nine months ended
		September 30,			September 30,
	2020		2019		2020		2019
Number of options over ordinary shares granted		1,882,966		3,733,359		14,851,182		15,477,255
Weighted average fair value of ordinary shares options	$	1.25	$	0.31	$	0.57	$	0.48
Number of additional options with a nominal exercise price granted		571,320		743,292		7,410,136		7,700,658
Weighted average fair value of options with a nominal exercise price	$	1.70		0.51	$	0.78	$	0.89